Everence Capital Management Inc. Invests $536,000 in ICU Medical, Inc. (NASDAQ:ICUI)

Everence Capital Management Inc. purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,940 shares of the medical instruments supplier’s stock, valued at approximately $536,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after acquiring an additional 11,991 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of ICU Medical by 21.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after acquiring an additional 55,588 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after buying an additional 145,485 shares during the period. Bank of New York Mellon Corp boosted its position in shares of ICU Medical by 11.5% in the second quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock worth $25,710,000 after buying an additional 22,310 shares during the period. Finally, Federated Hermes Inc. boosted its position in shares of ICU Medical by 9.3% in the second quarter. Federated Hermes Inc. now owns 215,808 shares of the medical instruments supplier’s stock worth $25,627,000 after buying an additional 18,301 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ICUI has been the subject of several recent analyst reports. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. KeyCorp increased their price objective on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Raymond James increased their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Finally, Jefferies Financial Group initiated coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.25.

ICU Medical Stock Down 1.1 %

ICUI stock opened at $178.93 on Tuesday. ICU Medical, Inc. has a twelve month low of $78.28 and a twelve month high of $188.53. The company has a market cap of $4.36 billion, a PE ratio of -73.03 and a beta of 0.66. The business’s 50-day simple moving average is $170.09 and its 200 day simple moving average is $132.47. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. During the same period last year, the business earned $1.58 earnings per share. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, research analysts anticipate that ICU Medical, Inc. will post 3.76 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,552 shares of company stock valued at $6,679,322. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.